Infections during induction therapy for children with acute lymphoblastic leukemia. The role of sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis

Pediatric Blood and Cancer

Volumn 55, Issue 2, 2010, Pages 304-308

  Rungoe, Christine ^a   Malchau, Emma Louise ^a   Larsen, Line Nordahl ^a   Schroeder, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute lymphoblastic leukemia; Antibiotic prophylaxis; Bacteremia; Children; Induction; Infection

Indexed keywords

COTRIMOXAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BACTEREMIA; BLOOD CULTURE; CENTRAL VENOUS CATHETER; CHILD; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 77955097892     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22423     Document Type: Article

References (25)

1. Hargrave DR, Hann II, Richards SM, et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALLVIII,X and XI). Br J Haematol 2001;112:293-299.
2. Katsimpardi K, Papadakis V, Pangalis A, et al. Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer 2006;14:277-284.
3. Lausen B, Schmiegelow K, Andreassen B, et al. Infections during induction therapy of childhood acute lymphoblastic leukemia - No association to mannose-binding lectin deficiency. Eur J Haematol 2006;76:481-487.
4. Rahiala J, Perkkio M, Riikonen P. Infections occurring during the courses of anticancer chemotherapy in children with ALL: A retrospective analysis of 59 patients. Pediatr Hematol Oncol 1998;15:165-174. (Pubitemid 28213546)
5. Schroder H, Lassen BT, Andersen ST, et al. Bacteremia in children with acute lymphoblastic leukemia. Ugeskr Laeger 1998;160:5487-5490.
6. Schroder H, Agger KE, Rosthoj S, et al. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia. Dan Med Bull 2001;48:275-277. (Pubitemid 33086242)
7. Conter V, Arico M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 1998;83:791-799.
8. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-2222.
9. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): The Dutch Childhood Oncology Group experience. Leukemia 2005;19:537-544.
10. Christensen MS, Heyman M, Mottonen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005;131:50-58.
11. Lode H. Co-trimoxazole from the therapeutic viewpoint. Infection 1987;15:S222-S226.
12. Kovatch AL, Wald ER, Albo VC, et al. Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children. Pediatrics 1985;76:754-760.
13. Goorin AM, Hershey BJ, Levin MJ, et al. Use of trimethoprim- sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis 1985;4:265-269. (Pubitemid 15093170)
14. van Eys EJ, Berry DM, Crist W, et al. Effect of trimethoprim/ sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987;59:19-23.
15. Pizzo PA, Robichaud KJ, Edwards BK, et al. Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 1983;102:125-133.
16. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-2275.
17. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987;317:1692-1698.
18. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: Advances in diagnosis, prevention, and management. Lancet Infect Dis 2007;7:645-657. (Pubitemid 47444563)
19. Graubner UB, Porzig S, Jorch N, et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:259-263.
20. Lex C, Korholz D, Kohlmuller B, et al. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma - A rationale for tailored supportive care. Support Care Cancer 2001;9:514-521.
21. Rolston KV. Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40:S246-S252.
22. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39:S25-S31.
23. Abbas AA, Fryer CJ, Paltiel C, et al. Factors influencing central line infections in children with acute lymphoblastic leukemia: Results of a single institutional study. Pediatr Blood Cancer 2004;42:325-331.
24. Adler A, Yaniv I, Steinberg R, et al. Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. J Hosp Infect 2006;62:358-365.
25. Andrivet P, Bacquer A, Ngoc CV, et al. Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. Clin Infect Dis 1994;18:199-206.